Mitochondrial Myopathies

Mitochondrial myopathies are a heterogeneous group of disorders caused by dysfunction of the mitochondrial respiratory chain, resulting in impaired oxidative phosphorylation and energy production in skeletal muscle. They arise from pathogenic variants in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) encoding mitochondrial proteins. With an estimated combined prevalence of 1 in 4,300 adults, mitochondrial diseases rank among the most common inherited metabolic disorders. Skeletal muscle is particularly vulnerable due to its high energy demands, and myopathy—ranging from exercise intolerance to profound weakness with respiratory failure—is a cardinal feature of many mitochondrial syndromes. The past decade has seen transformative advances in diagnostics, including next-generation sequencing and novel serum biomarkers (GDF-15, FGF-21), as well as the first FDA-approved therapies for specific mitochondrial disorders, marking a shift from purely supportive care toward disease-modifying treatment.

Mitochondrial Genetics

The Mitochondrial Genome

Each human cell contains hundreds to thousands of mitochondria, and each mitochondrion harbors 2–10 copies of the circular, 16.6 kb mitochondrial genome. The mtDNA encodes 13 subunits of the respiratory chain (complexes I, III, IV, and V), 22 transfer RNAs (tRNAs), and 2 ribosomal RNAs (rRNAs). The remaining ~1,500 mitochondrial proteins—including all subunits of complex II (succinate dehydrogenase)—are encoded by nuclear DNA, synthesized in the cytoplasm, and imported into the mitochondrion. This dual genetic control means that mitochondrial myopathies can follow maternal inheritance (mtDNA), autosomal dominant or recessive inheritance (nDNA), or arise sporadically from de novo mutations or somatic mtDNA deletions.

Heteroplasmy and the Threshold Effect

A critical concept in mitochondrial genetics is heteroplasmy—the coexistence of wild-type and mutant mtDNA within a single cell. The threshold effect refers to the minimum proportion of mutant mtDNA required to produce biochemical and clinical dysfunction, typically 60–90% depending on the specific mutation and tissue type. Skeletal muscle generally has a high threshold (~80–90% for point mutations), meaning significant mutant loads must accumulate before myopathy manifests. The threshold for large-scale mtDNA deletions tends to be lower (~65%).

Several factors contribute to clinical variability:

• Mitotic segregation: Random distribution of mitochondria during cell division causes heteroplasmy levels to shift between mother and offspring and among tissues within an individual
• Tissue-specific thresholds: Tissues with high oxidative demand (brain, skeletal muscle, cardiac muscle, retina) are affected at lower mutant loads than tissues with lower energy requirements
• Clonal expansion: Mutant mtDNA can accumulate preferentially within individual muscle fibers over time, producing mosaic patterns of respiratory chain deficiency visible on histochemistry
• Age-related accumulation: Somatic mtDNA mutations increase with age, contributing to late-onset presentations and variable expressivity within families

Nuclear DNA Contributions

Nuclear-encoded mitochondrial diseases account for approximately 75% of pediatric and a growing proportion of adult mitochondrial myopathies. Key categories include:

• mtDNA maintenance genes: POLG, TWNK, TK2, DGUOK, RRM2B, TYMP—mutations cause mtDNA depletion or multiple deletions
• Respiratory chain assembly factors: SURF1 (complex IV), NDUFAF1-6 (complex I), SCO2 (complex IV)—cause isolated complex deficiencies
• Mitochondrial translation: Genes encoding mitochondrial ribosomal proteins and aminoacyl-tRNA synthetases
• Mitochondrial dynamics: OPA1, MFN2 (fusion); DRP1 (fission)—affect mitochondrial morphology and distribution
• CoQ10 biosynthesis: COQ2, COQ4, COQ6, COQ8A—cause primary CoQ10 deficiency, which is treatable

Classic Mitochondrial Syndromes

CPEO and Kearns-Sayre Syndrome

Chronic progressive external ophthalmoplegia (CPEO) is the most common presentation of mitochondrial myopathy in adults. It is characterized by slowly progressive, bilateral, symmetric ptosis and limitation of eye movements that typically begins insidiously in young adulthood. Despite significant ophthalmoparesis, patients often do not report diplopia because the gradual onset allows adaptation. Proximal limb weakness, exercise intolerance, and dysphagia frequently accompany the ocular findings.

Kearns-Sayre syndrome (KSS) is defined by the triad of onset before age 20, progressive external ophthalmoplegia, and pigmentary retinopathy, plus at least one of the following: cardiac conduction block, cerebrospinal fluid protein >100 mg/dL, or cerebellar ataxia. KSS is typically caused by sporadic, large-scale single mtDNA deletions (most commonly the 4,977 bp “common deletion”). These deletions are heteroplasmic and often not detectable in blood, requiring muscle biopsy or urine sediment for diagnosis.

MELAS

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is the most clinically recognized mitochondrial syndrome. The m.3243A>G mutation in the MT-TL1 gene (tRNA^Leu(UUR)) accounts for ~80% of cases. Typical onset occurs in childhood or young adulthood, though late-onset presentations are well described. The stroke-like episodes are not true ischemic strokes; they result from mitochondrial angiopathy and neuronal metabolic failure, predominantly affecting the parieto-occipital cortex and not conforming to vascular territories.

Key clinical features include:

• Stroke-like episodes: Acute hemiparesis, hemianopia, cortical blindness, aphasia; often preceded by severe migraine-like headache and accompanied by seizures; MRI shows cortical/subcortical lesions crossing vascular territories
• Lactic acidosis: Elevated resting serum lactate; worsens during acute episodes; CSF lactate is often elevated even when serum lactate is normal
• Seizures: Both focal and generalized; may cluster during stroke-like episodes; status epilepticus can be precipitated by valproate
• Myopathy: Exercise intolerance and proximal weakness; may be mild compared to CNS manifestations
• Migraine-like headache: Recurrent, often with visual aura; frequently the earliest symptom
• Other features: Sensorineural hearing loss, diabetes mellitus, short stature, cardiomyopathy, GI dysmotility, cognitive decline

MERRF

Myoclonus epilepsy with ragged red fibers (MERRF) is caused in ~80% of cases by the m.8344A>G mutation in MT-TK (tRNA^Lys). Onset is typically in late childhood or early adulthood. The syndrome is named for its hallmark histopathological finding—ragged red fibers on modified Gomori trichrome stain.

Core clinical features include:

• Action myoclonus: Progressive, stimulus-sensitive, and debilitating; the most consistent clinical feature
• Generalized epilepsy: Tonic-clonic and myoclonic seizures; may precede other manifestations by years
• Cerebellar ataxia: Progressive gait and limb ataxia contributing to significant disability
• Myopathy: Proximal weakness and exercise intolerance; ragged red fibers are the histological hallmark
• Multiple lipomas: Symmetric, subcutaneous lipomas involving the neck and trunk; present in up to 50% of patients with m.8344A>G
• Other features: Sensorineural hearing loss, peripheral neuropathy, short stature, optic atrophy, cardiomyopathy

MNGIE

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by biallelic mutations in the TYMP gene encoding thymidine phosphorylase. Loss of enzyme activity leads to accumulation of thymidine and deoxyuridine, causing secondary mtDNA depletion, multiple deletions, and point mutations. Onset is typically in the second or third decade.

• GI dysmotility: The dominant and earliest feature; progressive gastroparesis, intestinal pseudo-obstruction, nausea, vomiting, abdominal pain, early satiety, and diarrhea
• Cachexia: Severe, progressive weight loss due to GI dysfunction and malabsorption; body weight often <60% of ideal
• Peripheral neuropathy: Demyelinating or mixed sensorimotor; often mistaken for chronic inflammatory demyelinating polyneuropathy
• Leukoencephalopathy: Diffuse white matter changes on MRI; typically asymptomatic
• CPEO and ptosis: Present in the majority of patients but often overshadowed by GI symptoms
• Treatment: Hematopoietic stem cell transplantation or orthotopic liver transplantation can restore thymidine phosphorylase activity; liver transplantation appears to have a more favorable safety profile

Primary Mitochondrial Myopathy

Primary mitochondrial myopathy (PMM) refers to mitochondrial disease in which skeletal muscle dysfunction is the predominant or sole clinical manifestation. The 280th ENMC International Workshop (2024) refined diagnostic criteria for PMM, distinguishing it from multisystem mitochondrial disease with incidental myopathy. PMM presents across a clinical spectrum:

• Exercise intolerance: The most common symptom; exertional fatigue, dyspnea, and post-exertional malaise disproportionate to the degree of weakness; may be the sole manifestation for years
• Proximal limb weakness: Gradually progressive; typically symmetrical, affecting hip and shoulder girdle muscles; may be accompanied by axial weakness
• CK levels: Normal or mildly elevated (usually <3× upper limit of normal); a markedly elevated CK should raise suspicion for an alternative or coexisting diagnosis
• Ptosis and ophthalmoparesis: Even in “isolated” mitochondrial myopathy, involvement of the extraocular muscles is common and should be specifically sought on examination
• Respiratory muscle involvement: Diaphragmatic weakness causing nocturnal hypoventilation may develop insidiously; overnight oximetry and pulmonary function testing are essential components of surveillance

mtDNA Depletion Syndromes

mtDNA depletion syndromes are autosomal recessive disorders caused by mutations in nuclear genes required for mtDNA replication or nucleotide supply, resulting in reduced mtDNA copy number in affected tissues. The myopathic form is most commonly caused by TK2 (thymidine kinase 2) mutations:

• Infantile-onset TK2 deficiency: Severe progressive myopathy presenting before age 2 years with hypotonia, feeding difficulty, respiratory failure; often fatal without treatment
• Childhood/adult-onset TK2 deficiency: More slowly progressive proximal weakness, respiratory insufficiency, CPEO; may mimic limb-girdle muscular dystrophy or spinal muscular atrophy
• Muscle biopsy: Severe COX-negative fibers, ragged red fibers, and markedly reduced mtDNA copy number by quantitative PCR
• Treatment breakthrough: Deoxynucleoside supplementation with doxecitine and doxribtimine (KYGEVVI) received FDA approval in November 2025—the first approved therapy for TK2 deficiency, reducing the risk of death by ~86% and enabling motor milestone recovery in 75% of treated patients

Diagnostic Approach

Serum Biomarkers

Genetic Testing

Genetic diagnosis is the cornerstone of confirming mitochondrial myopathy and has increasingly replaced muscle biopsy as the first-line investigation:

• Whole mtDNA sequencing: Detects point mutations and determines heteroplasmy levels in blood; should be the initial test when maternal inheritance is suspected (MELAS, MERRF)
• Long-range PCR or Southern blot: Required to detect single large-scale mtDNA deletions (CPEO, KSS), which are often undetectable by standard sequencing; muscle DNA has higher sensitivity than blood DNA for deletions
• Nuclear gene panels: Targeted panels for mitochondrial myopathy genes (50–300+ genes); particularly important for autosomal recessive mtDNA depletion syndromes (TK2, DGUOK, POLG, RRM2B)
• Whole exome/genome sequencing: Reserved for genetically unresolved cases; can identify novel genes; mitochondrial genome is often co-sequenced
• Tissue-specific testing: For somatic mtDNA mutations confined to muscle (e.g., some CPEO cases with single deletions), blood testing may be normal; mtDNA analysis from muscle biopsy or urinary epithelial cells is essential

Muscle Biopsy

While genetic testing has become the preferred initial diagnostic modality, muscle biopsy remains indispensable when genetic results are inconclusive, variants of uncertain significance are identified, or tissue-level confirmation of respiratory chain dysfunction is needed.

Exercise Testing

Standardized cycle ergometer exercise testing with serial lactate and pyruvate measurements can reveal abnormal anaerobic responses at low workloads. The forearm ischemic exercise test (grip test) has largely been replaced by non-ischemic protocols. Key findings suggestive of mitochondrial myopathy include:

• Exaggerated rise in venous lactate during submaximal exercise
• Elevated lactate-to-pyruvate ratio (>20) at rest or during exercise
• Markedly reduced peak oxygen consumption (VO₂max) relative to predicted values
• Second-wind phenomenon: improvement in exercise capacity after initial fatigue, reflecting increased blood flow and substrate delivery

Multisystem Screening

Mitochondrial myopathies rarely exist in isolation. Even when myopathy is the predominant feature, surveillance for multisystem involvement is essential:

Treatment

Supportive and Symptomatic Management

For most mitochondrial myopathies, treatment remains largely supportive, though evidence-based guidelines continue to evolve:

• Coenzyme Q10 (ubiquinone): 200–600 mg/day; acts as an electron carrier in the respiratory chain; most beneficial in primary CoQ10 deficiency syndromes where it can be disease-modifying; for other mitochondrial myopathies, evidence of benefit is limited but it is widely used given its favorable safety profile
• L-arginine for MELAS: Intravenous arginine (500 mg/kg in children; 10 g/m² in adults) within 3 hours of stroke-like episode onset, followed by continuous infusion for 3–5 days; oral L-arginine (150–300 mg/kg/day) for prophylaxis has been associated with reduced severity and frequency of stroke-like episodes in long-term follow-up studies
• Aerobic exercise: Supervised, moderate-intensity aerobic training (cycle ergometer, swimming, walking) 3–5 times per week improves exercise capacity, mitochondrial biogenesis, and quality of life; resistance training can complement aerobic exercise
• Nutritional support: Riboflavin (100–400 mg/day) for complex I deficiency and MADD; thiamine, alpha-lipoic acid, and carnitine supplementation have theoretical benefits but limited evidence
• Seizure management: Levetiracetam, lacosamide, and lamotrigine are generally well tolerated; clonazepam may help myoclonus in MERRF
• Cardiac management: Prophylactic pacemaker for progressive conduction disease in KSS; standard heart failure therapy for cardiomyopathy
• Respiratory support: Nocturnal non-invasive ventilation (BiPAP) for diaphragmatic weakness and nocturnal hypoventilation
• Hearing and vision: Hearing aids or cochlear implants for sensorineural hearing loss; cataract surgery as needed; ptosis surgery in select cases with careful anesthetic planning

Disease-Modifying and Approved Therapies

Emerging Therapies and Research

The therapeutic landscape for mitochondrial myopathies is evolving rapidly:

• Mitochondrial base editing: CRISPR-free approaches using engineered deaminases (DddA-derived cytosine base editors and adenine base editors) can correct pathogenic mtDNA point mutations; preclinical studies have demonstrated correction of the m.3243A>G MELAS mutation, with 51 known mtDNA point mutations amenable to A-to-G base editing
• Heteroplasmy shifting: Mitochondrially targeted endonucleases (mitoTALENs, mitoZFNs) selectively cleave mutant mtDNA, shifting heteroplasmy toward wild-type and reducing mutant load below the disease threshold; animal models show proof of concept
• Metabolic modulation of mtDNA selection: Small molecules that alter the metabolic environment (redox state, nucleotide pools) can influence mtDNA replication dynamics, preferentially reducing pathogenic mtDNA species—an approach termed “starve and sabotage”
• Mitochondrial donation (reproductive): Mitochondrial replacement therapy (MRT)—maternal spindle transfer or pronuclear transfer—enables women with pathogenic mtDNA mutations to have genetically related children with donor mitochondria; approved in the United Kingdom since 2015; the first births have been reported, though low-level carryover of maternal mtDNA has been observed in some offspring
• AAV-based gene therapy: Adeno-associated viral vectors expressing nuclear-encoded versions of mtDNA-encoded genes (allotopic expression) are in preclinical development for Leber hereditary optic neuropathy and have implications for broader mitochondrial disease applications
• NAD+ boosting agents: Niacin, nicotinamide riboside, and other NAD+ precursors aim to enhance mitochondrial biogenesis and compensate for respiratory chain dysfunction; clinical trials are ongoing
• Exercise mimetics: Bezafibrate and AICAR activate PGC-1α and mitochondrial biogenesis pathways; preliminary results in animal models show improved muscle function, but clinical data in humans remain limited

Prognosis

The prognosis of mitochondrial myopathies varies enormously depending on the specific genetic defect, tissue distribution of heteroplasmy, and degree of multisystem involvement. Isolated CPEO generally progresses slowly and is compatible with normal or near-normal lifespan, though quality of life may be significantly impaired. KSS carries a guarded prognosis due to the risk of sudden cardiac death from progressive conduction disease. MELAS has a median survival of approximately 35–40 years from birth, with stroke-like episodes causing cumulative neurological damage. MERRF is slowly progressive with significant disability from myoclonus and ataxia. Infantile-onset mtDNA depletion syndromes (TK2, DGUOK) historically had very poor prognosis, though deoxynucleoside therapy for TK2 deficiency has dramatically improved survival and motor outcomes. The approval of disease-specific therapies and the expanding pipeline of emerging treatments offer growing optimism for patients with mitochondrial myopathies.

References

1. Hirano M, Pitceathly RDS. Progressive external ophthalmoplegia. Handb Clin Neurol 2023;194:9–21.
2. Ahmed ST, Craven L, Russell OM, Turnbull DM, Vincent AE. Diagnosis and treatment of mitochondrial myopathies. Neurotherapeutics 2018;15(4):943–953.
3. Ng YS, Bindoff LA, Gorman GS, et al. Mitochondrial disease in adults: recent advances and future promise. Lancet Neurol 2021;20(7):573–584.
4. Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. Nat Rev Dis Primers 2016;2:16080.
5. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 2015;116(1–2):4–12.
6. Yatsuga S, Povalko N, Nishioka J, et al. MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 2012;1820(5):619–624.
7. Mancuso M, Orsucci D, Angelini C, et al. Redefining phenotypes associated with mitochondrial DNA single deletion. J Neurol 2015;262(5):1301–1309.
8. Davis RL, Liang C, Sue CM. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. Neurology 2016;86(21):2010–2015.
9. Yatsuga S, Fujita Y, Ishii A, et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol 2015;78(5):814–823.
10. Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, et al. Deoxycytidine and deoxythymidine treatment for thymidine kinase 2 deficiency. Ann Neurol 2017;81(5):641–652.
11. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology 2018;90(14):e1212–e1221.
12. Mok BY, de Moraes MH, Zeng J, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature 2020;583(7817):631–637.
13. Gammage PA, Viscomi C, Simard ML, et al. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo. Nat Med 2018;24(11):1691–1695.
14. Milone M. A pattern recognition approach to myopathy. Continuum (Minneap Minn) 2025;31(5):1244–1269.
15. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 2011;134(Pt 11):3326–3332.
16. Spinazzola D, Perez-Rodriguez D, Jezek J, Holt IJ. Mitochondrial DNA competition: starving out the mutant genome. Trends Pharmacol Sci 2024;45(3):225–242.